Tempus’s ARPA-H award adds clinical optionality, not yet a 10/5 long

Summary: Tempus AI was selected for up to $9.5 million of ARPA-H ADVOCATE funding to build and prospectively validate an autonomous heart-failure AI agent. The award is a fresh, non-dilutive catalyst layered on Q2 revenue of $382.5 million, 22% year-over-year growth, $820.7 million of cash and marketable securities, and raised 2026 revenue guidance of $1.595-$1.605 billion. The latest completed Nasdaq regular-session close was $58.97 on September 11. A generous base case clears 10%, but the credible adverse path remains above 5% and the gross reward-to-adverse-risk ratio is below 2:1. This is a long-only no-trade screen, not an executable recommendation. The paired signal is watch, with entry.price: null and execution.can_execute: false.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Tempus AI (TEM)	Long	ARPA-H clinical-AI validation and 22% growth versus valuation, dilution and execution risk	Sep. 9 ARPA-H award, Jul. 30 Q2 results, Sep. 11 close	Sep. 15 conference and multi-center study	Direct positioning unavailable; 3.67M shares traded	Reject: base +15.3%, adverse -23.7%, ratio 0.65:1	Liquid common stock; live execution structure not verified	Clinical validation, Personalis integration, valuation and dilution
2	Cerenome (CNSY)	Long	Up to $20M royalty-based financing and diagnostic scale-up versus cash burn	Sep. 10 financing, Aug. 14 Q2 results	Tranche milestones and CNSide billing	Direct positioning unavailable; small-cap tape	Reject: financing is conditional and downside is not bounded	Thin common stock; execution structure not verified	Royalty burden, milestones, liquidity and listing risk
3	Iveda (IVDA)	Long	Nasdaq compliance extension and AI deployments versus reverse-split and financing risk	Sep. 9 Nasdaq extension, latest filings	March 1, 2027 cure deadline and contract conversion	Direct positioning unavailable; low-priced tape	Reject: listing relief is not operating value	Thin common stock; execution structure not verified	Bid-price cure, dilution, contracts and liquidity

Selected opportunity: Tempus AI, for research only.

Why this one now: The ARPA-H award is a fresh primary catalyst that tests whether Tempus can turn its data and clinical infrastructure into an FDA-authorized autonomous-care product. It changes the evidence boundary from a pure growth-and-valuation screen, but it does not change the 10/5 downside math.

What should surprise the reader: The government award is up to $9.5 million, while Tempus has over $800 million of cash and a $10 billion-scale equity value. The award matters strategically and scientifically, but it is not large enough by itself to explain a 15% equity re-rating.

Why This Is the Best Opportunity Right Now

Tempus announced selection by ARPA-H for up to $9.5 million to build and clinically validate an autonomous heart-failure AI agent in a multi-center prospective study. ARPA-H describes the broader ADVOCATE program as a four-year, $62.7 million effort seeking FDA-authorized clinical AI for cardiovascular care. Tempus award ARPA-H program

Tempus’s Q2 release reported $382.5 million revenue, 22% growth, $8.0 million adjusted EBITDA, $5.6 million GAAP net income, $820.7 million of cash and marketable securities, a $460 million zero-coupon convertible offering, and raised 2026 revenue guidance to $1.595-$1.605 billion. Tempus Q2 results

The disagreement is whether the award and clinical-AI pipeline deserve a higher multiple, or whether Personalis integration, stock compensation, convertible dilution and clinical execution already absorb the upside.

Why This Can Move More Than 5% Soon

The September 15 Morgan Stanley conference is the next scheduled management event, while ARPA-H milestones and the prospective study provide a longer catalyst ladder. The latest completed Nasdaq close was $58.97 on September 11, with a $58.51-$60.35 range and 3,671,661 shares. TEM historical prices

No premarket quote is used. The market observation is the latest completed regular-session close.

10/5 Asymmetry Gate

The map uses the $58.97 reference. The top case is $75 if the award accelerates clinical adoption, Personalis integration works and growth stays near guidance. The base is $68 if Q3 execution and conference commentary preserve the 2026 guide. The bottom is $45 if clinical, integration, dilution or valuation pressure dominates.

Input	Result
Base move to $68	+15.31%
Credible adverse move to $45	-23.69%
Gross reward / adverse risk	0.65:1
Probability-weighted expected move	+8.41%
10/5 status	Reject

The favorable base move clears 10%, but the downside is not bounded near 5% and the gross ratio is below 2:1. The setup fails the Desk hurdle before costs.

What Should Surprise the Reader

Tempus has both a government-funded clinical-AI project and a profitable Q2 on a GAAP basis, but Q2 GAAP net income included $98.5 million of unrealized gains on marketable securities and $55.6 million of stock compensation and related payroll taxes. The recurring operating bridge still matters more than the headline profit.

The Setup

TEM combines oncology diagnostics, data licensing, AI models and a planned Personalis acquisition. The bull case is that clinical data, reimbursement and AI agents create compounding platform economics. The countercase is that the company spends heavily to prove clinical utility, issues or converts equity, and carries integration risk before the new product contributes material cash.

The Market Price

The latest completed Nasdaq reference was $58.97 on September 11, with a $58.51 low, $60.35 high and approximately 3.67 million shares. The historical feed is a market reference, not an executable quote. Spread, depth, venue quality, settlement, volume quality and exit liquidity were not verified.

The Mispricing

The market may be underpricing the strategic value of an ARPA-H-backed autonomous-care program. The mature counterargument is that the award is small relative to equity value and the clinical, reimbursement and integration path remains long. The mispricing, if any, is an option on validated clinical workflow, not a near-term earnings reset.

The Positioning

Direct current positioning, dealer exposure and borrow data were not reliably available. The 3.67 million-share session is observable but cannot distinguish event accumulation from risk reduction. Positioning confidence is low.

The Catalyst

Conference disclosure: verify milestones, award tranches, clinical design, FDA path and commercialization sequencing.
Operating print: reconcile oncology volume, MRD tests, data licensing, gross margin, adjusted EBITDA and operating cash.
Personalis integration: verify closing, share issuance, MRD revenue, reimbursement and cost synergies.
Clinical validation: verify enrollment, endpoints, safety, prospective evidence and regulatory submissions.

The cheapest falsification is any disclosure showing award tranches are delayed, the prospective study is not funded or enrolled, integration adds dilution without revenue, or adjusted growth fails to convert into cash.

The Payoff

The top case requires strategic validation and continued operating execution. The base assumes guidance holds but does not assign value to an FDA-authorized agent before clinical proof. The bottom case reflects the sensitivity of a high-growth stock to dilution, integration and valuation compression.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	25%	$75	+27.18%	Through Q3 and ARPA-H milestone disclosures	Clinical program advances, guidance holds, Personalis integration is accretive	Low
Base Case	50%	$68	+15.31%	Same window	Q3 execution supports guidance and conference clarifies award path	Medium
Bottom Case	25%	$45	-23.69%	Same window	Clinical, integration, dilution or valuation pressure dominates	Medium
Invalidation	n/a	Operating or clinical bridge contradicts option value	Thesis invalidated	Before entry	Cash, share count or clinical milestones fail	High

Probability-weighted expected value: $63.93, or +8.41% before costs.

Current market level and timestamp: $58.97 regular-session close reference, September 11, 2026.

Primary instrument: TEM common stock, unlevered.

10/5 favorable base move: +15.31% from the reference.

10/5 credible adverse move: -23.69% from the reference.

10/5 measurement basis: reference-only.

10/5 status: Reject.

Confidence: Medium-low. The award and Q2 figures are primary disclosures, but clinical milestones, Personalis closing and live execution structure remain unresolved.

The Kill Shot

The strongest counterparty view is that Tempus’s data network, reimbursement progress and government-funded clinical AI create an unusually strong platform. The load-bearing assumption is that clinical validation and integration will produce durable revenue and cash without excessive dilution. If the award remains a small research grant while cost and share count rise, the long case loses its differentiated edge.

What Could Go Wrong

Clinical endpoints can fail; FDA authorization can take longer; Personalis can be dilutive or difficult to integrate; reimbursement can lag; stock compensation and convertibles can expand the denominator; and AI regulation or privacy rules can slow deployment. Gaps, halts, slippage, settlement and exit-liquidity risk remain.

What Would Prove This Wrong

The screen would improve only if Tempus reports durable cash-generative growth, a clean Personalis share-count bridge, funded and enrolled ARPA-H milestones, and a credible regulatory path. The award announcement alone would not prove it.

Risk Audit

Evidence: ARPA-H award, Q2 results and guidance are primary; clinical and integration outcomes are future-dated.
Earnings quality: Q2 GAAP profit included unrealized investment gains and substantial stock compensation.
Positioning: direct current positioning unavailable; volume is not a flow diagnosis.
Execution: entry.price remains null and execution is blocked. No options, leverage, margin, market order or price-floor expression is supported.
Residual tails: clinical, regulatory, privacy, integration, financing and macro risks remain.

Best Trade Strategy

There is no trade-qualified strategy in this run. Keep TEM on a research watch only. Re-open after the conference, next quarterly filing and ARPA-H milestone disclosures reconcile recurring cash, clinical progress, Personalis dilution and regulatory path. Do not treat a government award as a price floor.

Sources

Tempus ARPA-H ADVOCATE award, September 9, 2026.
ARPA-H ADVOCATE program, September 9, 2026.
Tempus Q2 2026 results, July 30, 2026.
TEM historical prices, September 11, 2026 close.
Cerenome financing facility, September 10, 2026.
Iveda Nasdaq compliance extension, September 9, 2026.

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	5/5	Government-funded clinical AI versus small direct economics is explicit
Evidence base	4/5	Fresh award and primary Q2 results; clinical outcomes unresolved
Positioning and flows	2/5	Direct positioning unavailable; event tape is only a clue
Catalyst path	5/5	Conference, operating print, integration and study milestones are observable
Payoff architecture	4/5	Scenario map is explicit, but clinical and dilution inputs are missing
Invalidation discipline	5/5	Cash, share count, milestones and regulatory tests are monitorable
Differentiated insight	4/5	Award size must be separated from platform optionality
Client value	4/5	Shows why strategic validation can still fail 10/5

Total: 33/40. Publishable research quality, but the 10/5 and ratio failures force Reject/no-trade classification.

Bottom Line

Tempus’s ARPA-H award adds a real clinical-AI catalyst to a business that already reported 22% Q2 growth and $820.7 million of cash and marketable securities. But the award is small relative to equity value, Q2 profit quality is mixed, and Personalis and clinical milestones remain unresolved. The $58.97 reference supports a +15.31% base case, yet a credible -23.69% adverse path and a 0.65:1 ratio fail the Desk’s 10/5 hurdle. Publish the research, keep the entry null, and wait for clinical and denominator evidence.

AI Illustration Prompt

Editorial financial illustration: a clinical AI control room with a heart monitor, a prospective-study folder and a government award document marked “ARPA-H — UP TO $9.5M”; on one side, a luminous data network labeled “Q2 REVENUE $382.5M / CASH $820.7M,” and on the other, a cracked bridge labeled “CLINICAL VALIDATION / PERSONALIS INTEGRATION / SHARE COUNT”; restrained cobalt, cream, graphite and clinical teal palette with one amber warning accent; documentary realism, institutional magazine composition, generous negative space, no trading interface, no price prediction; add a subtle readable “The Mispricing Desk” watermark in the lower-right corner.